VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

VistaGen Therapeutics (NASDAQ: VTGN) announced participation in two investor conferences in March. The first is the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference from March 17-19, featuring a corporate presentation and a fireside chat on March 19 at 1:00 p.m. ET. The second conference, the Benzinga Biotech Small Cap Conference, is on March 25 at 10:05 a.m. ET. VistaGen aims to develop innovative treatments for anxiety, depression, and central nervous system disorders. More details can be found on the respective conference websites.

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen’s Chief Executive Officer, will participate in the following investor conferences in March:

Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference
Dates:	March 17th – 19th
Format:	Corporate Presentation & One-on-One Fireside Chat
Date:	Friday, March 19th at 1:00 p.m. ET
Format:	Fireside Chat with Jason McCarthy, Research Analyst
Website:	To attend the virtual conference, register here
	https://www.m-vest.com/events/2021-emerging-growth-virtual-conference

Benzinga Biotech Small Cap Conference
Date:	Thursday, March 25th at 10:05 a.m. ET
Format:	Corporate Presentation
Website:	To attend the virtual conference, register here
	https://events.benzinga.com/registration-page16068526119171607978331877

For more information regarding the conferences, please visit the sponsor conference websites.

About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

Company Contact
Mark A. McPartland
VistaGen Therapeutics, Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

FAQ

What conferences is VistaGen (VTGN) participating in March 2021?

VistaGen is participating in the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference from March 17-19 and the Benzinga Biotech Small Cap Conference on March 25, 2021.

When is VistaGen's fireside chat scheduled during the Maxim Group conference?

The fireside chat with VistaGen CEO Shawn Singh is scheduled for March 19, 2021, at 1:00 p.m. ET.

What is the focus of VistaGen's presentations at the investor conferences?

VistaGen's presentations will focus on developing innovative medicines for anxiety, depression, and other CNS disorders.

Where can I register for VistaGen's investor conferences?

You can register for the Maxim Group conference here and for the Benzinga conference here.